OHK Medical Devices Announces Publication of Kingston Hospital Study Results - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
OHK Medical Devices Announces Publication of Kingston Hospital Study Results


OHK Medical Devices Announces Publication of Kingston Hospital Study Results

PR Newswire

HAIFA, Israel, June 16, 2014 /PRNewswire/ --


OHK Medical Devices the leading manufacturer of the HemaClear® tourniquet announces the Journal of Surgery Research and Practice publication of Templeton-Ward et al study titled "The Use of the S-Mart Tourniquet in Hand Surgery: a Safe and Effective Way to Provide a Bloodless Field" (http://dx.doi.org/10.1155/2014/402184).

The study details the safety and effectiveness of exsanguination and bleeding control when the HemaClear is used in hand surgery in the UK.

The authors stressed the following advantages:

  • Reduced Tourniquet Times
  • Less Interference with the Operative Field
  • Outstanding field dryness

"In our experience, the use of the S-MART exsanguination tourniquet is an effective and safe way to provide a bloodless field in hand and wrist surgery" (Templeton-Ward et al, 2014).

The study was promoted by a derogative comment in Noordin et al (http://jbjs.org/content/91/12/2958) about the potential risks of the ultra-narrow HemaClear (S-MART). The study authors clearly state "We experienced very few complications as a result of its use as suggested in Noordin ' s article, and we feel that its benefits certainly outweigh any risks in its use."

About OHK

OHK Medical Devices, a privately held company headquartered in Haifa, Israel is the world leader in sterile tourniquet solutions. The HemaClear sterile tourniquet product is the first significant advancement in tourniquet solutions in over 10 years and the world's leading solution for bloodless orthopedic surgery. An innovative and groundbreaking technology has taken the orthopedic operating room to a new level. Since penetrating the market in 2008 HemaClear has been successfully used in over 600,000 procedures in over 2,000 operating rooms across 30 countries. For more information about OHK's HemaClear, visit http://www.hemaclear.com or contact Hallie Keren at Hallie@hemaclear.com or +972-54-782-7865

SOURCE OHK Medical Devices

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here